Ratings ImExHS Limited

Equities

Market Closed - Australian S.E. Other stock markets 01:59:33 2024-06-28 am EDT			5-day change	1st Jan Change
0.49 ^AUD	+8.89%		-.--%	-26.87%

Apr. 25	IMEXHS Completes AU$250,000 Conditional Placement	MT
Mar. 22	IMEXHS Renews Two Enterprise Software Contracts; Shares Up 3%	MT

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
The company shows low valuation levels, with an enterprise value at 0.81 times its sales.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

For the past year, analysts have significantly revised downwards their profit estimates.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
IMEXHS LIMITED	-26.87%	15.01M		-
VEEVA SYSTEMS INC.	-5.34%	29.46B		C
PRO MEDICUS LIMITED	+39.50%	9.42B		C-
SECTRA AB	+32.14%	4.33B		B-
EVOLENT HEALTH, INC.	-42.14%	2.19B		C-
VERADIGM INC.	-8.01%	1.63B	-	C+
OMNICELL, INC.	-31.12%	1.19B		B
LUNIT INC.	-41.51%	998M		-
B-SOFT CO.,LTD.	-50.69%	686M		-
SURGICAL SCIENCE SWEDEN AB	-29.81%	619M		-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality